BioSpace News Archive

Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, today announced publication of data from a nonclinical study of AVB-500, the company’s lead product candidate, which demonstrated reduction in tumor size and blood vessel density in animal models of clear cell renal cell carcinoma (ccRCC).

Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Company’s Board of Directors has authorized a reverse stock split of the Company’s common stock at a ratio of 1-for-100.

LifeMine Therapeutics today announced several key appointments to its drug discovery team to include, Iain McFadyen, Ph.D., as Chief Data Officer; Jared Cumming, Ph.D., as Senior Vice President and Head of Chemistry; and Dawn Thomspon, Ph.D., as Vice President and Head of Microbiology and Automation

On Target Laboratories, Inc., a privately held biotechnology company that is developing tumor-targeted imaging agents to improve cancer surgery, announced today the appointment of Kimberly Fabrizio as Vice President of Regulatory and Quality.

Integral Molecular, the industry leader in membrane protein solutions, has expanded its research facility to a second location to accommodate an upsurge in MPS Antibody Discovery partnerships and the progression of its internal therapeutic antibody pipeline

Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced that ORTHO™ Sera, a suite of extended antigen phenotyping, has been cleared by the U.S. Food and Drug Administration for use on the ORTHO VISION® Analyzer.

Marine fractured her spine while bending to help her disabled mother. Lo Lan broke her hip after tripping over a loose carpet in her home..

Inscopix has entered into a research collaboration with Astellas Research Institute of America LLC, a subsidiary of Astellas Pharma Inc., to develop novel preclinical drug screening assays for psychiatric disorders.

The report, global ventricular drainage devices market, has been added to Technavio’s catalog. It provides a comprehensive analysis of the market, including its global and regional market share as well as market segmentation based on product and geography for the forecast period 2019-2023.

The sessions may be accessed from the “Investors & Media” page of Regeneron’s website at http://investor.regeneron.com/events-and-presentations.